Drug Shortage Report for ACT BORTEZOMIB
| Report ID | 104930 |
| Drug Identification Number | 02438399 |
| Brand name | ACT BORTEZOMIB |
| Common or Proper name | ACT-BORTEZOMIB 3.5MG PINJ |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | BORTEZOMIB |
| Strength(s) | 3.5MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS SUBCUTANEOUS |
| Packaging size | 1 |
| ATC code | L01XX |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-01-31 |
| Estimated end date | 2020-05-31 |
| Actual end date | 2020-05-27 |
| Shortage status | Resolved |
| Updated date | 2020-05-29 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2020-05-29 | French | Compare |
| v3 | 2020-05-29 | English | Compare |
| v2 | 2020-05-29 | English | Compare |
| v1 | 2020-01-30 | English | Compare |
Showing 1 to 4 of 4